SOURCE: The Bedford Report

The Bedford Report

August 31, 2011 08:16 ET

Dendreon Effect Wearing Off -- Cancer Drug Stocks Begin to Recover

The Bedford Report Provides Equity Research on Dendreon & Oncothyreon

NEW YORK, NY--(Marketwire - Aug 31, 2011) - Cancer, projected by the World Health Organisation to become the leading cause of death worldwide this year, has already emerged as the most expensive disease, costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 billion a year, it is clearly a lucrative sector for drug developers. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on Dendreon Corporation (NASDAQ: DNDN) and Oncothyreon, Inc. (NASDAQ: ONTY). Access to the full company reports can be found at:

While the positive fundamentals are there, this month cancer drug stocks have suffered from what MarketWatch's Val Brickates Kennedy calls the "Dendreon Effect." The article reports that biotech companies whose stocks have taken heavy hits include those that are at early stages of marketing new treatments.

"Pretty much every company that had just launched a product or was about to launch a product got crushed," Leerink Swann analyst Howard Liang explains.

The Bedford releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Shares of Dendreon are slowly recovering from the significant drop they took earlier this month after the company announced that sales of Provenge, its $93,000 prostate cancer treatment, won't meet forecasts despite. Provenge is a therapy designed to train a patient's immune system to fight prostate cancer. Studies indicate it extended patients' lives by about four months. Last week the FDA approved a third facility where the company will make Provenge.

Oncothyreon specializes in the development of innovative therapeutic products for the treatment of cancer. The company's "Stimuvax" cancer vaccine is designed to induce an immune response to cancer cells and is currently in phase 3 trials.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information